{"analyses":[{"ciLowerLimit":"0.85","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.08","estimateComment":"Reference level = TAS x 8 weeks","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.47","paramType":"Hazard Ratio (HR)","paramValue":"0.96","statisticalComment":"Significance level = 0.05","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20","upperLimit":"27","value":"24"},{"groupId":"OG001","lowerLimit":"20","upperLimit":"27","value":"23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"752"},{"groupId":"OG001","value":"737"}],"units":"Participants"}],"description":"Disease-free survival time is defined as time from randomization to the date of disease progression or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Ten-year rate is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"OG000","title":"TAS x 8 Weeks"},{"description":"TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"OG001","title":"TAS x 28 Weeks"}],"paramType":"NUMBER","populationDescription":"Eligible patients without follow-up data","reportingStatus":"POSTED","timeFrame":"From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)","title":"Disease-free Survival (DFS) (10-year Rates Reported)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}